The traditional drug-delivery business model of service for hire has fallen from popularity. Big Pharmas are doing few deals of this sort, and investors want bigger returns than fees and royalties can provide. Start-ups with drug delivery technologies are increasingly using their platforms on their own behalf, to create products they can out-license or possibly market themselves. Now content--getting the molecules to be delivered--is an issue.
By Deborah Erickson
Drug delivery firms used to be strictly platform players, pitching a single method to many potential partners, as a service or technology for hire. But only Alza Corp. can...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
